Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegu, Amarendra, O’Connell, Sarah, Schmidt, Stephen D, O’Dell, Sijy, Talana, Chloe A., Lai, Lilin, Albert, Jim, Anderson, Evan, Bennett, Hamilton, Corbett, Kizzmekia S., Flach, Britta, Jackson, Lisa, Leav, Brett, Ledgerwood, Julie E., Luke, Catherine J., Makowski, Mat, Roberts, Paul C., Roederer, Mario, Rebolledo, Paulina A., Rostad, Christina A., Rouphael, Nadine G., Shi, Wei, Wang, Lingshu, Widge, Alicia T., Yang, Eun Sung, Beigel, John H., Graham, Barney S., Mascola, John R, Suthar, Mehul S., McDermott, Adrian, Doria-Rose, Nicole A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142657/
https://www.ncbi.nlm.nih.gov/pubmed/34031659
http://dx.doi.org/10.1101/2021.05.13.444010
Descripción
Sumario:SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-blocking antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose of mRNA-1273. At the peak of response to the second dose, all subjects had robust responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of mRNA-1273. Across all assays, B.1.351 had the greatest impact on antibody recognition, and B.1.1.7 the least. These data complement ongoing studies of clinical protection to inform the potential need for additional boost vaccinations.

Ejemplares similares